Picture [iito] Made Without Love 650x80px
Document › Details

Forbion Capital Partners. (3/13/18). "Press Release: Forbion Leads $19 Million Series B Financing of Escalier Biosciences to Advance Its Topical and Systemic RORgammat Therapies for Psoriasis and other Autoimmune Diseases".

Organisations Organisation Forbion Capital Partners (NL)
  Group Forbion (Group)
  Organisation 2 Escalier Biosciences B.V.
  Group Escalier Biosciences (Group)
Products Product ROR gamma inhibitor (orphan nuclear receptor gamma inhibitor)
  Product 2 venture capital
Index terms Index term Escalier Biosciences–Forbion: investment, 201803 financing round Series B totalling $19m incl lead + new investor Forbion
  Index term 2 Escalier Biosciences–SEVERAL: investment, 201803 financing round Series B $19m led by new investor Forbion with exiting investors NSC + BGV
Persons Person Boorsma, Marco (Forbion Capital Partners 201302)
  Person 2 Mohan, Raju (Ventyx Biosciences 202103 CEO + Founder before Escalier Biosciences + Akarna Therapeutics)

Forbion, one of the leading European life science venture capital firms, today announced that it led the $19 million Series B financing of Escalier Biosciences BV, a privately held biopharmaceutical company based in Nijmegen, The Netherlands. Escalier Biosciences is developing both oral and topical ROR?t drug candidates for psoriasis and other autoimmune diseases.

The financing round was completed by existing investors, New Science Ventures and BioGeneration Ventures and will be used to advance Escalier’s RORyt compounds through human proof-of-concept studies.

The nuclear hormone receptor RORyt has emerged as the “master” regulator of Th17 cell differentiation and the production of pro-inflammatory cytokines, such as IL-17A and IL-17F. Increased production of these cytokines has been linked to the pathophysiology of psoriasis. Small molecule inhibitors of ROR?t have been shown to reduce production of IL-17 in immune cells and are promising therapies for psoriasis and other autoimmune conditions.

Escalier expects its topical compound to enter the clinic in mid-2018.

“Escalier’s team has an impressive track record of developing novel compounds targeting diseases with significant unmet medical need,” stated Marco Boorsma, General Partner at Forbion who will join Escalier’s Board of Directors. “We are excited to participate in this financing with New Science Ventures and BioGeneration Ventures and in supporting Escalier’s efforts to develop best-in-class drugs for the treatment of psoriasis and other autoimmune diseases.”

“RORyt is a validated target for psoriasis and other autoimmune disorders and our drug candidates have the potential to provide the desired efficacy and safety in psoriasis patients that is currently unavailable with other topical or oral drugs,” said Raju Mohan, Ph.D., Chief Executive Officer of Escalier and previously CEO of Forbion’s portfolio company Akarna Therapeutics. “We are incredibly fortunate to have such a supportive syndicate of investors that share our passion in developing novel therapies for challenging targets, such as “RORyt."

Record changed: 2018-03-17


Picture [iito] Made Without Love 650x80px

More documents for Forbion (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top